Biopharmaceutical News and Research

RSS

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

WaferGen Biosystems, Inc. a leading developer of state-of-the-art genomic analysis systems, today announced that it is offering an early access program for high-throughput Single Nucleotide Polymorphism Genotyping through its new SmartChip Real-Time PCR System.

16 Feb 2011

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, gave a presentation about its E. coli O157 cattle vaccine at the First International One Health Congress in Melbourne, Victoria, Australia.

16 Feb 2011

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement.

16 Feb 2011

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus Pharmaceuticals, a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome.

16 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

Best Practices publishes new report on 'Innovations in Patient-Focused Initiatives'

For the biopharmaceutical industry, the changing healthcare marketplace has increased the importance - and difficulty - of interacting with patients to improve outcomes. New technologies and access restrictions have created both opportunities and challenges for approaching and engaging patient populations to improve disease control.

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

Dyadic issued seventh U.S. patent

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").

11 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

Cephalon to acquire Alba Therapeutics

Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

10 Feb 2011

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.

9 Feb 2011

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Inc. today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Biopharmaceutical News and Research

New fully human monoclonal antibodies to battle Chikungunya

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Best Practices publishes new report on 'Innovations in Patient-Focused Initiatives'

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

Dyadic issued seventh U.S. patent

Idenix announces updates on HCV and HIV clinical development programs

Cephalon to acquire Alba Therapeutics

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Event guide: World ADC San Diego eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News